NovoCure Limited (NVCR) CEO Sells $152,218.00 in Stock

NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger sold 6,919 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $22.00, for a total transaction of $152,218.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Asaf Danziger also recently made the following trade(s):

  • On Friday, November 3rd, Asaf Danziger sold 2,300 shares of NovoCure Limited stock. The shares were sold at an average price of $22.00, for a total transaction of $50,600.00.
  • On Wednesday, November 1st, Asaf Danziger sold 15,866 shares of NovoCure Limited stock. The shares were sold at an average price of $22.01, for a total transaction of $349,210.66.
  • On Monday, September 25th, Asaf Danziger sold 900 shares of NovoCure Limited stock. The shares were sold at an average price of $22.05, for a total transaction of $19,845.00.
  • On Wednesday, September 13th, Asaf Danziger sold 35,500 shares of NovoCure Limited stock. The shares were sold at an average price of $22.01, for a total transaction of $781,355.00.
  • On Thursday, September 14th, Asaf Danziger sold 37,272 shares of NovoCure Limited stock. The shares were sold at an average price of $22.01, for a total transaction of $820,356.72.

Shares of NovoCure Limited (NASDAQ NVCR) opened at $17.30 on Friday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.30 and a current ratio of 5.90. NovoCure Limited has a one year low of $6.00 and a one year high of $22.30.

NovoCure Limited (NASDAQ:NVCR) last released its earnings results on Thursday, October 26th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.07. The business had revenue of $50.10 million for the quarter, compared to analyst estimates of $43.45 million. NovoCure Limited had a negative net margin of 47.45% and a negative return on equity of 57.68%. NovoCure Limited’s revenue for the quarter was up 130.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.39) earnings per share. sell-side analysts expect that NovoCure Limited will post -0.63 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “NovoCure Limited (NVCR) CEO Sells $152,218.00 in Stock” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://transcriptdaily.com/2017/11/11/novocure-limited-nvcr-ceo-sells-152218-00-in-stock.html.

A number of brokerages recently issued reports on NVCR. Deutsche Bank AG reissued a “hold” rating and issued a $19.00 price objective (up from $18.00) on shares of NovoCure Limited in a research note on Monday, July 17th. BidaskClub raised shares of NovoCure Limited from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 31st. Zacks Investment Research cut shares of NovoCure Limited from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Mizuho initiated coverage on shares of NovoCure Limited in a research note on Wednesday, September 6th. They set a “buy” rating and a $25.00 target price on the stock. Finally, Wedbush reaffirmed an “outperform” rating and set a $25.00 target price (down previously from $29.00) on shares of NovoCure Limited in a research note on Friday, October 27th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $21.00.

Hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can raised its holdings in shares of NovoCure Limited by 1,919.7% during the second quarter. Bank of Montreal Can now owns 7,069 shares of the medical equipment provider’s stock valued at $122,000 after purchasing an additional 6,719 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of NovoCure Limited by 792.5% during the second quarter. BNP Paribas Arbitrage SA now owns 7,229 shares of the medical equipment provider’s stock worth $125,000 after acquiring an additional 6,419 shares in the last quarter. Nisa Investment Advisors LLC bought a new stake in shares of NovoCure Limited during the second quarter worth about $126,000. Trexquant Investment LP bought a new stake in shares of NovoCure Limited during the third quarter worth about $212,000. Finally, Fox Run Management L.L.C. bought a new stake in shares of NovoCure Limited during the second quarter worth about $225,000. Institutional investors and hedge funds own 35.88% of the company’s stock.

NovoCure Limited Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for NovoCure Limited (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply